Tweaking a protein expressed by most liver cancer cells has enabled scientists to make a vaccine that is exceedingly effective at preventing the disease in mice.
Alpha-Fetoprotein, or AFP – normally expressed during development and by liver cancer cells as well – has escaped attack in previous vaccine iterations because the body recognizes it as “self,” said Dr. Yukai He, immunologist at the Medical College of Georgia and Georgia Regents University Cancer Center.
Liver cancer is among the fastest-growing and deadliest cancers in the United States with a 17 percent three-year survival rate. Vaccines help direct the immune system to attack invaders by showing it a representative substance, called an antigen, that the body will recognize as foreign, in this case, AFP for liver cancer.
Read more . . .
The Latest on: Liver cancer
[google_news title=”” keyword=”Liver cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Liver cancer
- Overland Park boy, who battled cancer, in need of kidney transplanton March 28, 2024 at 6:50 pm
OVERLAND PARK, Kan. — An Overland Park boy is in need of a life-saving transplant. He’s 6-years-old and unlike most kids, he’s spent most of his life in and out of the hospital.
- Summit County woman diagnosed with lung cancer pleads for all Utahns to test for radonon March 28, 2024 at 1:00 pm
A Summit County woman wondered why she had never heard of radon, a radioactive gas you can't smell that is common in Utah and is the leading cause of lung cancer among non-smokers.
- The new weight-loss drugs and canceron March 28, 2024 at 12:01 pm
There is much to consider when it comes to using the new semaglutide drugs for weight loss, especially for cancer patients. Fred Hutch experts weight in.
- Aptamer Sciences Inc. Files IND Application for Innovative Liver Cancer Treatment AST-201: A Promising Approach to Address Under Medical Needson March 25, 2024 at 5:52 pm
Aptamer Sciences Inc. (KOSDAQ, 291650) announced the filing of an Investigational New Drug (IND) application for the phase 1 clinical trial of AST-201 with the Korean Ministry of Food and Drug Safety ...
- Helio Genomics Mulls New AI-Driven Dx Opportunities While Readying Liver Cancer Test for USon March 22, 2024 at 12:48 pm
The company recently published data on the MESA platform's ability to screen for colorectal cancer and is considering other testing opportunities.
- After Opdivo flop in liver cancer, Bristol Myers finds Yervoy combo could save liveson March 20, 2024 at 7:18 am
Bristol Myers Squibb is gunning for newly diagnosed unresectable liver cancer—again—after an immunotherapy setback five years ago. | Bristol Myers Squibb is gunning for newly diagnosed unresectable ...
- Bristol Myers hits late-stage win for liver cancer therapyon March 20, 2024 at 5:28 am
Bristol-Myers Squibb (NYSE:BMY) announced Wednesday that its immunotherapy combo, Opdivo plus Yervoy, reached its main goals in a late-stage trial as a first-line option for hepatocellular carcinoma, ...
- Bristol Myers' Opdivo-Yervoy combo meets main goal in liver cancer trialon March 20, 2024 at 4:35 am
Bristol Myers Squibb said on Wednesday a combination of Opdivo and Yervoy met the main goal of a late-stage study evaluating it as an initial treatment for a type of liver cancer.
- Immune evasion tactics of liver cancer cells revealedon March 19, 2024 at 10:13 am
as well as those investigating novel pathways for therapeutic targeting of liver cancer. HCC is the most frequent form of primary liver cancer, accounting for around 80% of cases. It is one of a ...
- A pioneering way to target the culprit behind a deadly liver canceron March 14, 2024 at 3:03 pm
Researchers have translated a cutting-edge tactic for treating genetic disorders into a fresh approach for potentially stymying cancer.
via Bing News